Effect of Serum SPARC Levels on Survival in Patients with Digestive Tract Cancer: A Post Hoc Analysis of the AMATERASU Randomized Clinical Trial
Observational studies suggest that physical activity may improve, whereas sarcopenia may worsen the survival of cancer patients. It has been suggested that secreted protein acidic and rich in cysteine (SPARC), one of the myokines that is secreted into the bloodstream by muscle contraction, has tumor...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2020-06-01
|
| Series: | Cancers |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2072-6694/12/6/1465 |
| _version_ | 1797566119996817408 |
|---|---|
| author | Taisuke Akutsu Eisaku Ito Mitsuo Narita Hironori Ohdaira Yutaka Suzuki Mitsuyoshi Urashima |
| author_facet | Taisuke Akutsu Eisaku Ito Mitsuo Narita Hironori Ohdaira Yutaka Suzuki Mitsuyoshi Urashima |
| author_sort | Taisuke Akutsu |
| collection | DOAJ |
| description | Observational studies suggest that physical activity may improve, whereas sarcopenia may worsen the survival of cancer patients. It has been suggested that secreted protein acidic and rich in cysteine (SPARC), one of the myokines that is secreted into the bloodstream by muscle contraction, has tumor-suppressive effects. Based on the hypothesis that serum SPARC level may be a potential prognostic biomarker, a post hoc analysis of the AMATERASU randomized, double-blind, placebo-controlled trial of postoperative oral vitamin D supplementation (2000 IU/day) in patients with stage I–III digestive tract cancer from the esophagus to the rectum (UMIN000001977) was conducted with the aim of exploring the association between serum SPARC levels after operation and survival. On multivariate analyses adjusting serum 25-hydroxyvitamin D, vitamin D supplementation, sarcopenia, body mass index, age, sex, cancer loci, stage, and adjuvant chemotherapy, patients with SPARC levels lower than the median level had a significantly higher risk for death than those with higher levels (hazard ratio, 2.25; 95% confidence interval, 1.25–4.05; <i>p</i> = 0.007), whereas there were no significant associations with other outcomes including recurrence. However, on the same multivariate analyses, sarcopenia was not a risk factor for death and/or relapse. These results suggest that serum SPARC levels may be a potential biomarker for death but not cancer relapse. |
| first_indexed | 2024-03-10T19:22:13Z |
| format | Article |
| id | doaj.art-daf6ff7364334182853598ff14cf43dd |
| institution | Directory Open Access Journal |
| issn | 2072-6694 |
| language | English |
| last_indexed | 2024-03-10T19:22:13Z |
| publishDate | 2020-06-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Cancers |
| spelling | doaj.art-daf6ff7364334182853598ff14cf43dd2023-11-20T02:52:09ZengMDPI AGCancers2072-66942020-06-01126146510.3390/cancers12061465Effect of Serum SPARC Levels on Survival in Patients with Digestive Tract Cancer: A Post Hoc Analysis of the AMATERASU Randomized Clinical TrialTaisuke Akutsu0Eisaku Ito1Mitsuo Narita2Hironori Ohdaira3Yutaka Suzuki4Mitsuyoshi Urashima5Division of Molecular Epidemiology, The Jikei University School of Medicine, 3-25-8, Nishi-Shimbashi, Minato-Ku, Tokyo 105-8461, JapanDepartment of Surgery, International University of Health and Welfare Hospital, 537-3 Iguchi, Nasushiobara, Tochigi 329-2763, JapanDepartment of Radiology, International University of Health and Welfare Hospital, 537-3 Iguchi, Nasushiobara, Tochigi 329-2763, JapanDepartment of Surgery, International University of Health and Welfare Hospital, 537-3 Iguchi, Nasushiobara, Tochigi 329-2763, JapanDepartment of Surgery, International University of Health and Welfare Hospital, 537-3 Iguchi, Nasushiobara, Tochigi 329-2763, JapanDivision of Molecular Epidemiology, The Jikei University School of Medicine, 3-25-8, Nishi-Shimbashi, Minato-Ku, Tokyo 105-8461, JapanObservational studies suggest that physical activity may improve, whereas sarcopenia may worsen the survival of cancer patients. It has been suggested that secreted protein acidic and rich in cysteine (SPARC), one of the myokines that is secreted into the bloodstream by muscle contraction, has tumor-suppressive effects. Based on the hypothesis that serum SPARC level may be a potential prognostic biomarker, a post hoc analysis of the AMATERASU randomized, double-blind, placebo-controlled trial of postoperative oral vitamin D supplementation (2000 IU/day) in patients with stage I–III digestive tract cancer from the esophagus to the rectum (UMIN000001977) was conducted with the aim of exploring the association between serum SPARC levels after operation and survival. On multivariate analyses adjusting serum 25-hydroxyvitamin D, vitamin D supplementation, sarcopenia, body mass index, age, sex, cancer loci, stage, and adjuvant chemotherapy, patients with SPARC levels lower than the median level had a significantly higher risk for death than those with higher levels (hazard ratio, 2.25; 95% confidence interval, 1.25–4.05; <i>p</i> = 0.007), whereas there were no significant associations with other outcomes including recurrence. However, on the same multivariate analyses, sarcopenia was not a risk factor for death and/or relapse. These results suggest that serum SPARC levels may be a potential biomarker for death but not cancer relapse.https://www.mdpi.com/2072-6694/12/6/1465SPARCsarcopeniamuscleosteonectinBM-40esophageal cancer |
| spellingShingle | Taisuke Akutsu Eisaku Ito Mitsuo Narita Hironori Ohdaira Yutaka Suzuki Mitsuyoshi Urashima Effect of Serum SPARC Levels on Survival in Patients with Digestive Tract Cancer: A Post Hoc Analysis of the AMATERASU Randomized Clinical Trial Cancers SPARC sarcopenia muscle osteonectin BM-40 esophageal cancer |
| title | Effect of Serum SPARC Levels on Survival in Patients with Digestive Tract Cancer: A Post Hoc Analysis of the AMATERASU Randomized Clinical Trial |
| title_full | Effect of Serum SPARC Levels on Survival in Patients with Digestive Tract Cancer: A Post Hoc Analysis of the AMATERASU Randomized Clinical Trial |
| title_fullStr | Effect of Serum SPARC Levels on Survival in Patients with Digestive Tract Cancer: A Post Hoc Analysis of the AMATERASU Randomized Clinical Trial |
| title_full_unstemmed | Effect of Serum SPARC Levels on Survival in Patients with Digestive Tract Cancer: A Post Hoc Analysis of the AMATERASU Randomized Clinical Trial |
| title_short | Effect of Serum SPARC Levels on Survival in Patients with Digestive Tract Cancer: A Post Hoc Analysis of the AMATERASU Randomized Clinical Trial |
| title_sort | effect of serum sparc levels on survival in patients with digestive tract cancer a post hoc analysis of the amaterasu randomized clinical trial |
| topic | SPARC sarcopenia muscle osteonectin BM-40 esophageal cancer |
| url | https://www.mdpi.com/2072-6694/12/6/1465 |
| work_keys_str_mv | AT taisukeakutsu effectofserumsparclevelsonsurvivalinpatientswithdigestivetractcanceraposthocanalysisoftheamaterasurandomizedclinicaltrial AT eisakuito effectofserumsparclevelsonsurvivalinpatientswithdigestivetractcanceraposthocanalysisoftheamaterasurandomizedclinicaltrial AT mitsuonarita effectofserumsparclevelsonsurvivalinpatientswithdigestivetractcanceraposthocanalysisoftheamaterasurandomizedclinicaltrial AT hironoriohdaira effectofserumsparclevelsonsurvivalinpatientswithdigestivetractcanceraposthocanalysisoftheamaterasurandomizedclinicaltrial AT yutakasuzuki effectofserumsparclevelsonsurvivalinpatientswithdigestivetractcanceraposthocanalysisoftheamaterasurandomizedclinicaltrial AT mitsuyoshiurashima effectofserumsparclevelsonsurvivalinpatientswithdigestivetractcanceraposthocanalysisoftheamaterasurandomizedclinicaltrial |